Date: 2016-01-30
Type of information: Collaboration agreement
Compound:
Company: Novasep (France) Advanced Biotherapeutics Consulting (France)
Therapeutic area: Technology - Services
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On January 13, 2016, Novasep and Advanced Biotherapeutics Consulting (ABC), a service provider that leverages the expertise of the Nantes Gene Therapy Institute led by Philippe Moullier, announced they have entered into a CDMO (Contract Development Manufacturing Organization) partnership. This partnership enables the companies to provide their respective customers with the full range of services relating to Adeno-Associated Virus (AAV) viral vector production. Novasep’s ambition is to build and offer an AAV excellence platform to the gene therapy market. The partnership with ABC provides Novasep customers with access to expert early-stage drug development services; this complements Novasep’s existing capacity in AAV vector development and production. For ABC, the deal is a means to further support its customers after early-stage development, when production is scaling up. For AAV drug developers, this partnership will facilitate the technology transfer from one partner to the other and therefore simplify and accelerate the development phase for joint customers. Novasep brings its industrial process design, clinical and commercial manufacturing track record. ABC is skilled in viral vector design, process and analytical method developments, and early-stage production. Its expertise covers all steps of gene-based drug development for translating an early stage preclinical project to a clinical trial and beyond, particularly in the field of genetic diseases. ABC areas of expertise are preclinical proof-of-concept, regulatory toxicology studies, viral vector manufacturing and quality control, and regulatory strategies to meet EMA requirements. It relies on the Nantes Gene Therapy Institute headed by Philippe Moullier, MD, PhD, an internationally recognized expert.
Financial terms:
Latest news:
